scholarly journals Immunoblastic lymphoma

Author(s):  
A Cuneo ◽  
GM Rigolin ◽  
F Cavazzini
Pathology ◽  
1990 ◽  
Vol 22 (2) ◽  
pp. 103-105 ◽  
Author(s):  
John K.C. Chan ◽  
C.S. Ng ◽  
P.K. Hui

1984 ◽  
Vol 76 (5) ◽  
pp. 861-867 ◽  
Author(s):  
William R. Strand ◽  
Peter M. Banks ◽  
Robert A. Kyle

Blood ◽  
2001 ◽  
Vol 97 (3) ◽  
pp. 744-751 ◽  
Author(s):  
Antonino Carbone ◽  
Annunziata Gloghini ◽  
Luigi M. Larocca ◽  
Daniela Capello ◽  
Francesco Pierconti ◽  
...  

Abstract This study was aimed at defining the histogenesis of the pathologic spectrum of lymphoma arising in the context of human immunodeficiency virus (HIV) infection. Toward this aim, 87 AIDS-related non-Hodgkin lymphomas (AIDS-NHL) and 16 Hodgkin lymphomas arising in HIV+ patients (HIV-HL) were comparatively analyzed for the expression pattern of several B-cell histogenetic markers, including BCL-6 (expressed by centroblasts and centrocytes), MUM1/IRF4 (expressed by late centrocytes and post–germinal center [GC] B cells), and CD138/syn-1 (expressed by post-GC B cells). Expression of MUM1, BCL-6, and syn-1 segregated 3 major phenotypic patterns among AIDS-NHL and HIV-HL: (1) the BCL-6+/MUM1−/syn-1− pattern, selectively clustering with a large fraction of AIDS-Burkitt lymphoma (17 of 19) and of systemic AIDS–diffuse large cell lymphoma (12 of 16); (2) the BCL-6−/MUM1+/syn-1−pattern, associated with a fraction of AIDS-immunoblastic lymphoma (8 of 24); and (3) the BCL-6−/MUM1+/syn-1+ pattern, associated with systemic and primary central nervous system immunoblastic lymphoma (14 of 24) and with primary effusion lymphoma (10 of 10), plasmablastic lymphoma of the oral cavity (7 of 7), and HIV-HL (15 of 16). Analysis of nonneoplastic lymph nodes showed that the 3 phenotypic patterns detected in AIDS-NHL and HIV-HL correspond to distinct stages of physiologic B-cell development—centroblasts (BCL-6+/MUM1−/syn-1−), late GC/early post-GC B cells (BCL-6−/MUM1+/syn-1−), and post-GC B cells (BCL-6−/MUM1+/syn-1+). Expression of the Epstein-Barr virus-encoded latent membrane protein-1 clustered with the BCL-6−/MUM1+/syn-1+profile throughout the clinicopathologic spectrum of AIDS-NHL and HIV-HL. Overall, these results define novel histogenetic subsets of AIDS-NHL and HIV-HL and may provide novel tools for refining the diagnosis of these disorders.


Orbit ◽  
2003 ◽  
Vol 22 (3) ◽  
pp. 171-175 ◽  
Author(s):  
Paolo Palma ◽  
Luca Ravalli ◽  
Roberto Modestino ◽  
Filippo Grisanti ◽  
Francesco Casillo ◽  
...  

1992 ◽  
Vol 27 (5) ◽  
pp. 626-628 ◽  
Author(s):  
Anne-Marie Houle ◽  
Gordon A. McLorie ◽  
Bernard M. Churchill ◽  
Antoine E. Khoury ◽  
Elizabeth Harvey ◽  
...  

Blood ◽  
1998 ◽  
Vol 92 (5) ◽  
pp. 1549-1555 ◽  
Author(s):  
Cliona M. Rooney ◽  
Colton A. Smith ◽  
Catherine Y.C. Ng ◽  
Susan K. Loftin ◽  
John W. Sixbey ◽  
...  

Abstract Epstein-Barr virus (EBV) causes potentially lethal immunoblastic lymphoma in up to 25% of children receiving bone marrow transplants from unrelated or HLA-mismatched donors. Because this complication appears to stem from a deficiency of EBV-specific cytotoxic T cells, we assessed the safety and efficacy of donor-derived polyclonal (CD4+ and CD8+) T-cell lines as immunoprophylaxis and treatment for EBV-related lymphoma. Thirty-nine patients considered to be at high risk for EBV-induced lymphoma each received 2 to 4 intravenous infusions of donor-derived EBV-specific T lymphocytes, after they had received T-cell–depleted bone marrow from HLA-matched unrelated donors (n = 33) or mismatched family members (n = 6). The immunologic effects of this therapy were monitored during and after the infusions. Infused cells were identified by detection of the neo marker gene. EBV-specific T cells bearing theneo marker were identified in all but 1 of the patients. Serial analysis of DNA detected the marker gene for as long as 18 weeks in unmanipulated peripheral blood mononuclear cells and for as long as 38 months in regenerated lines of EBV-specific cytotoxic T cells. Six patients (15.5%) had greatly increased amounts of EBV-DNA on study entry (>2,000 genome copies/106 mononuclear cells), indicating uncontrolled EBV replication, a complication that has had a high correlation with subsequent development of overt lymphoma. All of these patients showed 2 to 4 log decreases in viral DNA levels within 2 to 3 weeks after infusion and none developed lymphoma, confirming the antiviral activity of the donor-derived cells. There were no toxic effects that could be attributed to prophylactic T-cell therapy. Two additional patients who did not receive prophylaxis and developed overt immunoblastic lymphoma responded fully to T-cell infusion. Polyclonal donor-derived T-cell lines specific for EBV proteins can thus be used safely to prevent EBV-related immunoblastic lymphoma after allogeneic marrow transplantation and may also be effective in the treatment of established disease. © 1998 by The American Society of Hematology.


1998 ◽  
Vol 9 (5) ◽  
pp. 511-518 ◽  
Author(s):  
F. Cabanillas ◽  
J. Rodriguez-Diaz Pavón ◽  
F.B. Hagemeister ◽  
P. McLaughlin ◽  
M.A. Rodriguez ◽  
...  

2004 ◽  
Vol 66 (2) ◽  
pp. 189-191 ◽  
Author(s):  
Makoto OHSHIMA ◽  
Takehito MORITA ◽  
Masumi SAWADA ◽  
Akinori SHIMADA ◽  
Hideko KOBAYASHI ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document